← All trials
NCT04850820
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Apr 20, 2021
- Last posted
- Apr 21, 2021
- Enrollment
- 10
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- University of TorontoReponsible party - principal investigator
- University of TorontoOverall official - principal investigator
- Iovate Health Sciences International IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.